Jul 3, 2026

Featuring an interview with Dr Rana R McKay, including the following topics:

• Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
• Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
• Combination therapy using relugolix; factors affecting persistence and...

Jul 2, 2026

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics:

• Overview of the current landscape of prostate cancer (0:00)
• Mechanism of action of androgen deprivation therapy (ADT) (3:51)
• Findings from the Phase III HERO study evaluating relugolix versus leuprolide for...

Jun 23, 2026

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:

• Introduction (0:00)
• Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)
• Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)

CME information...

Jun 16, 2026

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)
• Current Hormonal...

May 27, 2026

Interview conducted on March 11, 2026, by Dr Neil Love, including the following topics:

• Circulating tumor DNA (ctDNA)-guided adjuvant therapy with atezolizumab for muscle-invasive bladder cancer (MIBC) (0:00)
• Use of ctDNA in guiding systemic treatment selection for patients with urothelial bladder cancer (10:03)
• ctDNA...